Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair
Author:
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference44 articles.
1. Global cancer statistics;A Jemal;CA Cancer J Clin,2011
2. Emerging trends in hepatocellular carcinoma incidence and mortality;B Njei;Hepatology,2015
3. Management of hepatocellular carcinoma: an update;J Bruix;Hepatology,2011
4. Diagnosis and treatment of hepatocellular carcinoma;HB El-Serag;Gastroenterology,2008
5. Novel advancements in the management of hepatocellular carcinoma in 2008;JM Llovet;Journal of hepatology,2008
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers;Current Drug Delivery;2024-05
2. Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells;Biomedicine & Pharmacotherapy;2024-04
3. Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials;Recent Patents on Anti-Cancer Drug Discovery;2023-11
4. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma;Journal of Cellular Biochemistry;2022-10
5. BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism;PHARMAZIE;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3